Full-Time

Software Test Engineer III

Posted on 4/30/2025

Omnicell

Omnicell

1,001-5,000 employees

Medication management and pharmacy automation platform

No salary listed

No H1B Sponsorship

Cranberry Twp, PA, USA

Hybrid

Hybrid/Office environment – Cranberry Township, PA; Ability to travel 10% of the time; Able to work from assigned location without housing or relocation assistance from Omnicell

Category
QA & Testing (1)
Required Skills
Agile
SCRUM
Requirements
  • Programming experience in one or more object-oriented languages
  • Experience creating automation tests and leveraging test frameworks interfacing with some of the following: RESTful services, Message Queues, Relational Databases, Web Applications
  • Demonstrated analytical and problem-solving skills
  • Good interpersonal communication skills
  • Knowledgeable in Agile/Scrum software development lifecycle management
Responsibilities
  • Work as part of a team to design, test, deploy, maintain and improve software
  • Collaborate with software and quality engineers in all phases of development and testing
  • Tests code and product behaviors by creating automated tests at varying layers (component integration, system, performance, UI) and performing manual and exploratory testing across the system
  • Effectively troubleshoots complex scenarios, isolates and analyzes defects providing detailed steps and conditions for defect reproduction
  • Collaborate with cross-functional teams on documentation and training
  • Understand how Omnicell solutions meet our customers' needs and how our suite of products are used across the continuum of care
Desired Qualifications
  • Healthcare Industry Experience
  • 3+ years of experience in C# and the .NET Framework
  • 2+ years of experience with a microservices architecture
  • 1+ years of experience in Angular 4 or above
  • 1+ years of public cloud experience
  • 1+ year experience healthcare or pharmaceutical experience working with interfaces such as HL7, FHIR. EDI and working with PHI
  • Understanding of Internationalization / Localization
  • Understanding of Inventory / warehouse management
  • Knowledge of distributed source code control like Git

Omnicell provides medication management solutions and adherence tools for health systems and pharmacies, combining pharmacy automation devices with cloud-based software to automate dispensing, manage inventory, and support patient adherence. The products mix hardware and a cloud platform that coordinates dispensing, inventory control, and clinical data through dashboards and analytics. Compared with competitors, Omnicell emphasizes a cloud-first software approach with a clear path to software-as-a-service and a hybrid direct-plus-partner sales model for end-to-end pharmacy automation and data services. Its goal is to realize the Autonomous Pharmacy by using automation and intelligent services to improve pharmacy care and patient outcomes while building recurring revenue.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Mountain View, California

Founded

1992

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue reached $310 million, while non-GAAP EBITDA nearly doubled.
  • Management estimates the XT replacement opportunity exceeds $2.5 billion long term.
  • Recurring revenue is approaching $700 million, supporting a SaaS valuation re-rate.

What critics are saying

  • Titan XT shipments begin in late 2026, delaying meaningful revenue contribution.
  • BD Pyxis and GPO-aligned rivals are attacking Omnicell's replacement cycle.
  • Hospital budget freezes and tariff costs compress hardware margins and stall upgrades.

What makes Omnicell unique

  • Omnicell's Autonomous Pharmacy unifies cabinets, software, and services across care settings.
  • Titan XT and OmniSphere turn existing XT installs into upgrade paths.
  • On-site pharmacy experts improved productivity and safety, strengthening implementation outcomes.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Omnicell who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Company Match

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Mar 5th, 2026
Omnicell's Titan XT cabinet launch divides analysts on $1.3B revenue outlook

Omnicell's analyst narrative centres on its Titan XT cabinet system and a potential hospital replacement cycle, though opinions diverge sharply on timing. The modelled fair value holds at $57.43 amid mixed price target revisions. BofA, Benchmark and KeyBanc have taken bullish stances, with KeyBanc upgrading to Overweight at $60, citing competitive wins and a cabinet refresh cycle. Conversely, Piper Sandler cut its target by $14, flagging execution and timing risks around the same Titan XT story. Omnicell issued Q1 2026 revenue guidance of $300 million to $310 million and full-year guidance of $1.215 billion to $1.255 billion. The company has launched Titan XT in the US, with international rollout expected later in 2026.

Yahoo Finance
Feb 28th, 2026
Omnicell targets $2.4B revenue by 2031 with shift to AI-driven pharmacy automation

Omnicell, Inc. is transitioning from hardware-driven revenue to a software and services model, aiming to double revenue from $1.18 billion to $2.4 billion by 2031, according to a bullish thesis on Danny's Substack. The company is expanding through strategic acquisitions like ANiGENT and developing its "Autonomous Pharmacy" vision using AI and robotics. The healthcare automation firm benefits from high switching costs, over 900 patents and a large installed base. Recurring revenue is approaching 50% of total revenue, with margins expected to expand from low teens to mid-20s. Bulls believe the market currently undervalues Omnicell as a hardware vendor, creating potential for significant rerating as it shifts towards healthcare IT, with shares trading at $38.61 as of 18 February.

Yahoo Finance
Feb 2nd, 2026
Omnicell beats Q3 revenue estimates by 5%, stock surges 64% since earnings report

Omnicell, a provider of medication management automation and adherence tools for healthcare systems and pharmacies, reported third-quarter revenues of $310.6 million, up 10% year on year and exceeding analysts' expectations by 5%. The company also beat earnings per share estimates. "We are pleased with the strong financial performance delivered in the third quarter," said Randall Lipps, Omnicell's chairman, president and chief executive officer. The stock has risen 64% since reporting results and currently trades at $48.49. The healthcare technology for providers sector faces mixed conditions, with opportunities from AI-driven tools and government digitisation incentives offset by challenges including long sales cycles, slow adoption rates, and tightening hospital budgets. The four companies tracked in this sector reported satisfactory third-quarter results overall, though share prices have declined 5.3% on average since earnings.

Specialty Pharmacy Continuum
Aug 18th, 2025
Texas Children's Hospital Adopts RFID for OR Med Management

This May, medication and supply management technology company Omnicell launched a new radio frequency identification (RFID)-enabled device to manage medications in the operating room.

StreetInsider
Mar 24th, 2025
Omnicell (OMCL) appoints Perry Genova as CTO

Omnicell, Inc. (Nasdaq: OMCL), a leader in transforming the pharmacy and nursing care delivery model, today announced that Perry A. Genova, PhD, will join the Company as Senior Vice President, Chief Technology Officer, effective March 31, 2025.

INACTIVE